FDA committee votes to make peptides more widely available

An FDA advisory committee voted narrowly to recommend allowing specialized compounding pharmacies to formulate and sell seven specific peptides (BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon) directly to consumers, moving them from a high-risk list to the 503A Bulks List despite FDA scientists' warnings about insufficient safety and efficacy data.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.